比利时UCB公司向CBC和Mubadala公司出售中国神经学和过敏业务,售价680万美元。 Belgian firm UCB sells Chinese neurology and allergy business to CBC and Mubadala for $680m.

比利时生物制药公司UCB正将其中国神经学和过敏企业出售给设在新加坡的CBC公司和阿布扎比的Mubadala公司,售价680万美元。 Belgian biopharmaceutical firm UCB is selling its Chinese neurology and allergy business to Singapore-based CBC and Abu Dhabi's Mubadala for $680m. 这笔交易包括UCB的神经学组合和抗过敏药物,以及祖海市的一个制造点。 The deal includes UCB's neurology portfolio and anti-allergy medicines, as well as a manufacturing site in Zhuhai city. 这一出售将使UCB能够专注于中国的创新和伙伴关系,因为它将其战略目标与中国市场不断变化的需求相协调. This sale will enable UCB to focus on innovation and partnerships in China, as it aligns its strategic goals with the evolving demands of the Chinese market.